Dynavax to Participate in Upcoming Investor Conferences

Rhea-AI Summary

Dynavax Technologies (Nasdaq: DVAX), a commercial-stage biopharmaceutical company focused on innovative vaccine development, has announced its participation in two major upcoming investor conferences:

• TD Cowen 45th Annual Healthcare Conference on March 4 at 1:10 p.m. ET
• Barclays 27th Annual Global Healthcare Conference on March 11 at 10:00 a.m. ET

The company will provide webcasted presentations accessible through their investor relations website. Dynavax currently markets two commercial products: HEPLISAV-B vaccine, approved in the U.S., EU, and UK for hepatitis B virus prevention in adults 18+, and CpG 1018 adjuvant, used in HEPLISAV-B and various COVID-19 vaccines.

Argus Session date unavailable

+2.09% session move Open Argus

Details

News Market Reaction – DVAX

The recorded move for DVAX in the trading session of this news was +2.09%.

Data tracked by StockTitan Argus. Session date unavailable.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

EMERYVILLE, Calif., Feb. 25, 2025 /PRNewswire/ -- Dynavax Technologies Corporation (Nasdaq: DVAX), a commercial-stage biopharmaceutical company developing and commercializing innovative vaccines, today announced that the Company will participate in the following upcoming investor conferences:

• TD Cowen 45th Annual Healthcare Conference on Tuesday, March 4 at 1:10 p.m. ET
  
  
• Barclays 27th Annual Global Healthcare Conference on Tuesday, March 11 at 10:00 a.m. ET

The presentations will be webcast and may be accessed through the "Events & Presentations" page on the "Investors" section of the Company's website at https://investors.dynavax.com/events-presentations.

About Dynavax
Dynavax is a commercial-stage biopharmaceutical company developing and commercializing innovative vaccines to help protect the world against infectious diseases. The Company has two commercial products, HEPLISAV-B^® vaccine [Hepatitis B Vaccine (Recombinant), Adjuvanted], which is approved in the U.S., the European Union and the United Kingdom for the prevention of infection caused by all known subtypes of hepatitis B virus in adults 18 years of age and older, and CpG 1018^® adjuvant, currently used in HEPLISAV-B and multiple adjuvanted COVID-19 vaccines. For more information about our marketed products and development pipeline, visit www.dynavax.com.

For Investors/Media:
Paul Cox
pcox@dynavax.com
510-665-0499

Nicole Arndt
narndt@dynavax.com
510-665-7264

View original content to download multimedia:https://www.prnewswire.com/news-releases/dynavax-to-participate-in-upcoming-investor-conferences-302385222.html

SOURCE Dynavax Technologies

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

When is Dynavax (DVAX) presenting at the TD Cowen Healthcare Conference?

Dynavax will present at the TD Cowen 45th Annual Healthcare Conference on Tuesday, March 4 at 1:10 p.m. ET.

What are the main commercial products of Dynavax (DVAX)?

Dynavax has two main products: HEPLISAV-B vaccine for hepatitis B prevention and CpG 1018 adjuvant used in various vaccines.

Where is HEPLISAV-B vaccine approved for use?

HEPLISAV-B is approved in the United States, European Union, and United Kingdom for adults 18 years and older.

How can investors access Dynavax's (DVAX) conference presentations?

Investors can access the webcasted presentations through the 'Events & Presentations' page on Dynavax's investor website at investors.dynavax.com.

What is the schedule for Dynavax's (DVAX) Barclays Conference presentation?

Dynavax will present at the Barclays 27th Annual Global Healthcare Conference on Tuesday, March 11 at 10:00 a.m. ET.